MINIMED TEST DEVICE GAINS OK FROM PANEL.Byline: Ben Sullivan Daily News Staff Writer A government panel Friday recommended approval of a blood glucose monitoring blood glucose monitoring Sugar monitoring Lab medicine The periodic testing of serum glucose in Pts known to have DM. See Bedside glucose monitoring, Beta cell implants, Diabetes, Glucometer, Glycosylated hemoglobin, Non-Invasive glucose monitoring. system developed by MiniMed Inc. but said the company must conduct further tests on the product. The panel of experts unanimously but conditionally recommended the U.S. Food and Drug Administration approve the product, the first to provide continuous testing of diabetics' blood sugar levels. The device would make unnecessary the finger pricks diabetics must now conduct up to three times per day to draw blood for testing. The FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. is not bound by the panel's recommendation. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. analyst Sam (1) (Security Accounts Manager) The part of Windows NT that manages the database of usernames, passwords and permissions. A SAM resides in each server as well as in each domain controller. See PDC and trust relationship. Chang at investment bank Volpe Brown Whelan, the FDA panel quibbled with the patient population on which MiniMed tested the device. Chang said the panel asked MiniMed to test more minorities and Type II diabetics, because the bulk of the previous subjects were white, Type I sufferers. Chang said it was unclear whether MiniMed must conduct the tests before or concurrently with sales of the product. Even if the FDA does give MiniMed the nod, it will be for use of the glucose sensor A device that measures or detects a real-world condition, such as motion, heat or light and converts the condition into an analog or digital representation. An optical sensor detects the intensity or brightness of light, or the intensity of red, green and blue for color systems. only in a physician office setting. A consumer device is likely two to three years away, Chang said. Still, the company was all smiles Friday after its meeting with the panel. ``It's very good news,'' said spokesman Pete Escallier. ``It's very common for a new product like this to come out with some conditions. But we've been waiting for this a long time and are looking forward to implementing our plan.'' News of the FDA panel recommendation came after the close of trading Friday. MiniMed shares closed down $3 to $85.25, after falling as low as $79.125 in midday
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion